ERBB2 and cancer: Cancer-therapy-related cardiotoxicity includes various conditions that may be induced by different classes of agents, such as chemotherapeutic drugs like anthracyclines, proteasome inhibitors, and microtubule inhibitors; targeted therapies (e.g., anti-HER2 drugs, anti-angiogenic agents); immunotherapy; and newer drugs, such as ADCs.